Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabine Mueller

Showing results (191-200 of 223) with videos related to

Pageof 23
Sort By:
Brain Pathology (Zurich, Switzerland)|November 25, 2021
Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomasEmily A Sloan, Rohit Gupta, Christian Koelsche, et al.
Neuro-Oncology|March 30, 2024
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma modelsDaniel de la Nava, Iker Ausejo-Mauleon, Virginia Laspidea, et al.
Cancer Cell|October 6, 2023
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memoryIker Ausejo-Mauleon, Sara Labiano, Daniel de la Nava, et al.
Arxiv|December 18, 2023
A multi-institutional pediatric dataset of clinical radiology MRIs by the Children's Brain Tumor NetworkAriana M Familiar, Anahita Fathi Kazerooni, Hannah Anderson, et al.
Neuro-Oncology|March 12, 2025
Germline analysis of an international cohort of pediatric diffuse midline glioma patientsMarion K Mateos, Pamela Ajuyah, Noemi Fuentes-Bolanos, et al.
Neuro-Oncology|May 19, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade GliomaChelsea Kotch, Sebastien Perreault, Phoebe Power, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
mRNA aggregates harness danger response for potent cancer immunotherapyHector R Mendez-Gomez, Anna DeVries, Paul Castillo, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Acta Neuropathologica|August 9, 2022
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto-Hope G Lucas, Emily A Sloan, Rohit Gupta, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Pageof 23

Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
Brain Pathology (Zurich, Switzerland)|November 25, 2021
Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomasEmily A Sloan, Rohit Gupta, Christian Koelsche, et al.
Neuro-Oncology|March 30, 2024
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma modelsDaniel de la Nava, Iker Ausejo-Mauleon, Virginia Laspidea, et al.
Cancer Cell|October 6, 2023
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memoryIker Ausejo-Mauleon, Sara Labiano, Daniel de la Nava, et al.
Arxiv|December 18, 2023
A multi-institutional pediatric dataset of clinical radiology MRIs by the Children's Brain Tumor NetworkAriana M Familiar, Anahita Fathi Kazerooni, Hannah Anderson, et al.
Neuro-Oncology|March 12, 2025
Germline analysis of an international cohort of pediatric diffuse midline glioma patientsMarion K Mateos, Pamela Ajuyah, Noemi Fuentes-Bolanos, et al.
Neuro-Oncology|May 19, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade GliomaChelsea Kotch, Sebastien Perreault, Phoebe Power, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
mRNA aggregates harness danger response for potent cancer immunotherapyHector R Mendez-Gomez, Anna DeVries, Paul Castillo, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Acta Neuropathologica|August 9, 2022
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto-Hope G Lucas, Emily A Sloan, Rohit Gupta, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Pageof 23